Default company panoramic image
Logo

ProteaPex Therapeutics

ProteaPex Therapeutics is developing an innovative disease modifying therapeutic to treat osteoarthritis in companion animals. This new class of therapeutic,...

  • Stage Product In Development
  • Industry Biotechnology
  • Location Philadelphia, PA, USA
  • Currency USD
  • Founded May 2011
  • Employees 3
  • Website proteapextherapeutics.com

Company Summary

ProteaPex Therapeutics is developing an innovative disease modifying therapeutic to treat osteoarthritis in companion animals. This new class of therapeutic, the Extracellular Matrix Protection Factor, is a safe and effective intra-joint injection that reduces the pain and damage caused by osteoarthritis.

Team

  • Default avatar
    Jeffrey Boily
    Chairman & CEO

    Jeff Boily is a serial entrepreneur and investor with over 30 years of global life sciences experience. Jeff's emerging company and fund raising experience includes start-ups, growth stage and turnaround in pharmaceuticals, biotechnology, drug delivery, medical devices, and clinical informatics. He gained large company executive experience at Abbott, Rogers and Wyeth including Fort Dodge Animal Health. He has led IPO efforts, raised capital in th

  • Default avatar
    Marina D'Angelo D'Angelo, PhD
    Chief Science Officer

    Marina D’Angelo, PhD has over 25 years of experience in cell differentiation and cartilage biology. The major emphasis of her research endeavors has been chondrocyte biology. Over the last 20 years she has studied the role of growth factors and enzymes in normal chondrocyte differentiation and the disease pathway, osteoarthritis. She has held a faculty appointment at several major institutions in the Philadelphia area, including University of Pen